Companies /Healthcare
Idexx Laboratories Inc
NASDAQ: IDXX Diagnostics & Research
$700.65
▼ $3.58 (−0.51%) today
Markets closed · 10:14pm ET

IDEXX Laboratories (IDXX) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
IDXX vs Market · 30-day return after each reportIDXXS&P 500
−7%0%+7%−3.9%−1.3%Q2 23+11.6%+6.7%Q1 25−6.2%+2.8%Q2 25−0.8%+0.2%Q3 25−3.2%−2.0%Q4 25−0.1%+1.9%Q1 26−10.0%+0.2%Q2 26
−7%0%+7%Q2 23Q2 25Q4 25Q2 26
IDXX EPS Trend · estimate vs actualEstimateActual
$0$2$4$2.47$2.67Q2 23$2.84$2.96Q1 25$3.30$3.63Q2 25$3.14$3.40Q3 25$2.94$3.08Q4 25$3.41$3.47Q1 26$3.72$4.01Q3 26
$0$2$4Q2 23Q2 25Q4 25Q3 26
IDXX Revenue Trend · estimate vs actualEstimateActual
$0$400.0M$800.0M$1.2B$934.4M$943.6MQ2 23$996.5M$998.4MQ1 25$1.1B$1.1BQ2 25$1.1B$1.1BQ3 25$1.1B$1.1BQ4 25$1.1B$1.1BQ1 26$1.2B$1.2BQ3 26
$0$400.0M$800.0M$1.2BQ2 23Q2 25Q4 25Q3 26

How Often Does IDEXX Laboratories Beat Earnings Estimates?

IDEXX Laboratories beat EPS estimates in 7 of its last 8 reported quarters, and has beaten 8 quarters in a row.

IDXX quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Q3 EPS included a $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 per share in tax benefits from share-based compensation, and a $0.04 per share benefit from year-over-year currency changes, while absorbing acquisition impacts including transaction-related costs; company-reported comparable EPS was $3.96. $4.01 est. $3.72 +7.91% $1.2B est. $1.2B +1.83%
Q2 2026 $4.27 — $1.2B —
Q1 2026 $3.47 est. $3.41 +1.74% $1.1B est. $1.1B +2.88%
Q4 2025 Q4 GAAP diluted EPS includes $0.09 per share positive impact from currency changes and $0.07 per share in tax benefits from share-based compensation; company-reported non-GAAP comparable EPS was $2.92. $3.08 est. $2.94 +4.85% $1.1B est. $1.1B +1.73%
Q3 2025 $3.40 est. $3.14 +8.29% $1.1B est. $1.1B +3.16%
Q2 2025 $3.63 est. $3.30 +9.97% $1.1B est. $1.1B +3.95%
Q1 2025 $2.96 est. $2.84 +4.06% $998.4M est. $996.5M +0.20%
Q2 2023 $2.67 est. $2.47 +8.10% $943.6M est. $934.4M +0.99%
Q1 2022 $2.27 est. $2.26 +0.44% $836.5M est. $839.7M −0.38%

Figures from SEC filings and company reports. Not investment advice.